Разработка автоматизированной системы измерений количества топливного газа

Цель работы – разработка автоматизированной системы управления системы измерения количества и качества топливного газа с использованием ПЛК и выбор SCADA-системы. В этой работе была разработана система контроля и управления технологическим процессом СИКТГ на базе промышленных контроллеров Delta V MD Plus, с использованием SCADA-системы DeltaV. В процессе исследования проводились: Изучение технологического процесса в целом и его отдельных участков; Подбор датчиков и исполнительных механизмов; Изучение необходимой технической документации; Разработка и анализ схем для осуществления поставленной задачи.The purpose of the work is the development of an automated control system for measuring the quantity and quality of fuel gas using a PLC and selecting a SCADA system. In this work, a system for monitoring and controlling the technological process of SICT was developed on the basis of industrial controllers Delta V MD Plus, using the DeltaV SCADA system. In the process of research were conducted: Study of the technological process as a whole and its individual sections; Selection of sensors and actuators; Study of the necessary technical documentation; Development and analysis of schemes for the implementation of the task

Portrayals of the Holocaust in English history textbooks, 1991–2016: continuities, challenges and concerns

This study examines portrayals of the Holocaust in a sample of 21 secondary school history textbooks published in England between 1991 and 2016. Evaluated against internationally recognized criteria and guidelines, the content of most textbooks proved very problematic. Typically, textbooks failed to provide clear chronological and geographical frameworks and adopted simplistic Hitler-centric, perpetrator-oriented narratives. Furthermore, textbooks paid limited attention to pre-war Jewish life, the roots of antisemitism, the complicity of local populations and collaborationist regimes, and the impact of the Holocaust on people across Europe. Based on these critical findings, the article concludes by offering initial recommendations for textbook improvement

Tumor and Stromal Cell Targeting with Nintedanib and Alpelisib Overcomes Intrinsic Bladder Cancer Resistance.

Bladder cancer is a highly prevalent tumor, requiring the urgent development of novel therapies, especially for locally advanced and metastatic disease. Nintedanib is a potent antifibrotic angio-kinase inhibitor, which has shown clinical efficacy in combination with chemotherapy in patients with locally advanced muscle-invasive bladder cancer. Nintedanib inhibits fibroblast growth factor receptors (FGFRs), validated targets in patients with bladder cancer harboring FGFR3/2 genetic alterations. Here, we aimed at studying its mechanisms of action to understand therapy resistance, identify markers predictive of response, and improve the design of future clinical trials. We have used a panel of genetically well-characterized human bladder cancer cells to identify the molecular and transcriptomic changes induced upon treatment with nintedanib, in vitro and in vivo, at the tumor and stroma cell levels. We showed that bladder cancer cells display an intrinsic resistance to nintedanib treatment in vitro, independently of their FGFR3 status. However, nintedanib has higher antitumor activity on mouse xenografts. We have identified PI3K activation as a resistance mechanism against nintedanib in bladder cancer and evidenced that the combination of nintedanib with the PI3K inhibitor alpelisib has synergistic antitumor activity. Treatment with this combination is associated with cell-cycle inhibition at the tumoral and stromal levels and potent nontumor cell autonomous effects on α-smooth muscle actin-positive tumor infiltrating cells and tumor vasculature. The combination of nintedanib with PI3K inhibitors not only reversed bladder cancer resistance to nintedanib but also enhanced its antiangiogenic effects.We thank Roland Varecka and Donat Alpar for excellent technical assistance with the generation of the next-generation sequencing libraries and for sequencing, Irene Mill an for her assistance in the integrated RNA-seq analysis, Flora Díaz for help with in vivo experiments and animal care, and the Biology Section of the Experimental Therapeutics Program and the Histopathology Unit of CNIO for valuable contributions. This work was supported, in part, by a research grant from Boehringer Ingelheim and by a grant from Fundaci on Científica de la Asociaci on Espanola ~ Contra el C ancer to F.X. Real. CNIO is supported by Ministerio de Ciencia, Innovaci on y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015– 0510, cofinanced by the Fondo Social Europeo. S. Corral was supported by Fellowship PRE2018–085808 from Agencia Estatal de Investigaci on, cofinanced by Fondo Social Europeo. I. Zagorac received a Juan de la Cierva Fellowship from Ministerio de Ciencia, Innovaci on y Universidades.S

Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models

Background: Gastric adenocarcinoma (GAC) is the fourth leading cause of cancer death worldwide. Systemic chemotherapy is a preferred treatment option for advanced and recurrent GAC, but response rates and survival prolongation remain limited. Tumor angiogenesis plays a critical role in GAC growth, invasion and metastasis. We investigated the antitumor efficacy of nintedanib, a potent triple angiokinase inhibitor for VEGFR-1/2/3, PDGFR-α/β and FGFR-1/2/3, alone or in combination with chemotherapy, in preclinical models of GAC. Methods: Animal survival studies were performed in peritoneal dissemination xenografts in NOD/SCID mice using human GAC cell lines MKN-45 and KATO-III. Tumor growth inhibition studies were performed in subcutaneous xenografts in NOD/SCID mice using human GAC cell lines MKN-45 and SNU-5. The mechanistic evaluation involved Immunohistochemistry analyses in tumor tissues obtained from subcutaneous xenografts. In vitro cell viability assays were performed using a colorimetric WST-1 reagent. Results: In MKN-45 GAC cell-derived peritoneal dissemination xenografts, animal survival was improved by nintedanib (33%), docetaxel (100%) and irinotecan (181%), while oxaliplatin, 5-FU and epirubicin had no effect. The addition of nintedanib to docetaxel (157%) or irinotecan (214%) led to a further extension in animal survival. In KATO-III GAC cell-derived xenografts carrying FGFR2 gene amplification, nintedanib extended survival by 209%. Again, the addition of nintedanib further enhanced the animal survival benefits of docetaxel (273%) and irinotecan (332%). In MKN-45 subcutaneous xenografts, nintedanib, epirubicin, docetaxel and irinotecan reduced tumor growth (range: 68-87%), while 5-FU and oxaliplatin had a smaller effect (40%). Nintedanib addition to all chemotherapeutics demonstrated a further reduction in tumor growth. Subcutaneous tumor analysis revealed that nintedanib attenuated tumor cell proliferation, reduced tumor vasculature and increased tumor cell death. Conclusion: Nintedanib showed notable antitumor efficacy and significantly improved taxane or irinotecan chemotherapy responses. These findings indicate that nintedanib, alone and in combination with a taxane or irinotecan, has the potential for improving clinical GAC therapy